Swallowing becomes a problem long before most people notice it. A slight hesitation between bite and gulp, a sentence abandoned halfway through because the muscles involved in forming it are no longer quite keeping up. For people living with amyotrophic lateral sclerosis, these aren’t minor inconveniences. They’re milestones in a relentless countdown, the bulbar symptoms that often signal how quickly the disease is advancing.
That’s what makes a set of trial results published this week in JAMA Neurology important. The drug in question, PrimeC, is not a new molecule. It’s a fixed-dose combination of two existing medicines: celecoxib, a common anti-inflammatory, and ciprofloxacin, a widely prescribed antibiotic. The idea that pairing them might do something meaningful against one of neurology’s most brutal diseases sounds, on first hearing, almost too simple. It may not be.
The PARADIGM trial ran at four clinical sites in Italy, Canada and Israel, enrolling 68 people with confirmed ALS over roughly 18 months. Participants either took PrimeC twice daily for six months, then continued for another year, or took a placebo before crossing over to the active drug. Both groups were well-matched at the start, with a mean score of 37.5 on the ALS Functional Rating Scale Revised, the standard measure used to track how patients fare across speech, swallowing, walking, breathing and a range of other motor functions.
By month six the difference was modest: people taking PrimeC scored about 2.2 points higher than those on placebo, a gap that didn’t quite reach statistical significance. But by month 18, after the delayed-start cohort had been on the drug for a full year, the separation between the two groups had grown to nearly eight points. The biggest contributor was bulbar function, that cluster of abilities governed by the brain stem: speech, swallowing, chewing. People who’d been on PrimeC from the beginning were, on average, holding onto those capacities considerably longer.
The gap is striking partly because, once both groups are receiving the same treatment, you’d expect their trajectories to converge. In delayed-start trial designs, that convergence is actually the typical finding; active treatment effects tend to level out once everyone is on the drug. Here they didn’t. That persistence is arguably the most intriguing part of the dataset. It’s compatible with the idea that PrimeC is doing something more than just managing symptoms, that it might be slowing the underlying course of disease rather than merely modulating how patients feel at a given point. The team is careful not to overstate this, as well they should be, since the trial wasn’t designed or powered to assess efficacy. But the pattern is there.
“The importance of following up on potential therapies that can slow the course of ALS is extraordinarily high for patients and families,” said Merit Cudkowicz, Executive Director of the Mass General Brigham Neuroscience Institute and the trial’s first author. “We are determined to accelerate the development of therapies for people living with ALS.”
The biology behind PrimeC is, in a way, a recognition that ALS is several problems at once. Motor neuron death in ALS isn’t driven by a single mechanism; neuroinflammation, disrupted iron metabolism and a kind of molecular interference in how the cell processes small regulatory RNA molecules all appear to be tangled together in the disease process. Ciprofloxacin, beyond its antibiotic activity, turns out to chelate iron and modulate a class of molecules called microRNAs. Celecoxib targets the inflammatory arm. In cell culture and animal models, the two compounds work synergistically, each nudging a different part of a common pathway.
The PARADIGM data suggest something similar might be happening in people. Ferritin, a protein that stores iron and rises predictably as ALS worsens, stayed flat in PrimeC-treated participants while climbing in the placebo group. Transferrin, which tends to fall in ALS, was preserved. Four specific microRNAs, each previously associated with either ALS severity or increased mortality risk, were significantly downregulated after six months of treatment. These changes didn’t merely correlate with clinical outcomes; in the placebo group, rising ferritin was inversely correlated with function, and that correlation disappeared in the treatment group. The molecular footprint of the disease, or at least part of it, seemed to be getting quieter.
Jeremy Shefner, professor of neurology at Barrow Neurological Institute and the paper’s corresponding author, said this alignment across measurement types is what gives the findings their weight: “What stands out about the PARADIGM study is that multiple clinical endpoints suggest the same level of clinical benefit and that multiple biomarkers are consistent with clinical endpoints.”
Neurofilament light chain, the protein the field has become perhaps overly fond of using as a readout of neuronal damage, didn’t change significantly. That’s a limitation worth noting, though the researchers suggest the trial may simply have been too small and too short to detect movement in a marker with high individual variability.
There are other limits. Sixty-eight participants is not many. The trial was funded by NeuroSense Therapeutics, the company developing PrimeC, and the sponsor had a role in data analysis and manuscript preparation. Independent replication matters here, and the researchers are calling for exactly that: a phase 3 trial in a larger, properly powered cohort. Whether the functional signal will hold, and whether the safety profile (mild to moderate gastrointestinal and vascular side effects, mostly temporary) remains acceptable at scale, are the two questions that now need answering.
ALS has seen enough promising phase 2 results crumble in phase 3 to warrant genuine caution. But the convergence of clinical and molecular signals, including the bulbar function preservation that matters so much in daily life, is the kind of coherent pattern that rarely emerges by accident. The next trial will be harder to dismiss.
DOI / Source: https://doi.org/10.1001/jamaneurol.2026.0230
Frequently Asked Questions
PrimeC is an experimental oral drug combining two already-approved medicines, celecoxib (an anti-inflammatory) and ciprofloxacin (an antibiotic), reformulated together in a single extended-release tablet. Most approved ALS treatments, such as riluzole and edaravone, work through a single mechanism, while PrimeC is designed to simultaneously target three pathological processes: neuroinflammation, disrupted iron metabolism, and abnormal microRNA activity. It would be taken twice daily alongside standard-of-care therapies.
The ALS Functional Rating Scale Revised (ALSFRS-R) is a standardised questionnaire that tracks ability across twelve areas: speech, salivation, swallowing, handwriting, cutting food, dressing, turning in bed, walking, climbing stairs, breathing, and a few others. Scores range from 0 to 48, with higher scores reflecting better function. In a disease where untreated patients typically lose around half a point per month, an 8-point gap at 18 months represents roughly 16 months of functional preservation, though this comparison should be treated as illustrative rather than a clinical calculation.
MicroRNAs are short, non-coding RNA molecules that regulate how genes are expressed without being translated into protein themselves. In ALS, specific microRNAs are dysregulated in ways that impair the health of motor neurons and amplify inflammatory signals. The PARADIGM trial found that four microRNAs previously linked to ALS severity and survival risk were significantly reduced after six months of PrimeC treatment, a finding consistent with the drug’s proposed mechanism via the ciprofloxacin component.
In a delayed-start trial, some participants begin active treatment immediately while others receive placebo first, then switch to the drug. If a treatment only manages symptoms, the late-starters tend to catch up once they begin taking it. If trajectories stay separated even after both groups are on the drug, it suggests the early-treated group gained a durable advantage, which is more consistent with a disease-modifying effect than a purely symptomatic one. In PARADIGM, the functional gap between groups persisted through 18 months despite all participants receiving PrimeC in the second phase, though the researchers caution the trial was not designed to establish this.
PrimeC is not approved for clinical use. The PARADIGM results support advancing to a phase 3 trial, which would enrol a larger population and be designed to formally assess whether the drug slows ALS progression. Phase 3 trials in ALS typically take several years to complete, and regulatory approval would require those results to be positive and safety data from larger numbers to remain acceptable.
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.
Key Takeaways
- PrimeC, a combination of celecoxib and ciprofloxacin, shows potential in slowing ALS progression according to the PARADIGM trial.
- The trial involved 68 ALS patients and noted an 8-point improvement in bulbar function over 18 months compared to placebo.
- Results suggest PrimeC may modify disease mechanisms rather than just alleviate symptoms, as indicated by consistent clinical and molecular outcomes.
- Changes in biomarkers, like ferritin and specific microRNAs, align with improved patient function.
- Researchers call for a phase 3 trial to confirm results and address safety for wider use in ALS patients.